**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 31328**

**Manuscript Type: ORIGINAL ARTICLE**

***Prospective Study***

**Long-term results of TP concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma**

Zhu ht *et al*. concurrent chemoradiotherapy for ESCC

Han-Ting Zhu, Da-Shan Ai, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao

**Han-Ting Zhu, Da-Shan Ai,** **Hua-Rong Tang, Harun Badakhshi,** **Jian-hong Fan, Jia-Ying Deng,** **Jun-Hua Zhang,** **Yun Chen, Zhen Zhang, Yi Xia,** **Xiao-Mao Guo,** **Guo-Liang Jiang, Kuai-Le Zhao,** Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

**Hua-Rong Tang,** Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, Zhejiang Province, China

**Harun Badakhshi,** Department of Radiation Oncology, Charité School of Medicine and Centre for Cancer Medicine, 14195 Berlin, Germany

**Jian-hong Fan,** Department of Gynecology, Renhe Hospital, Shanghai 443001, China

**Athor contributions:** Zhu HT and Ai DS contributed equally to this work; Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Xia Y and Zhao KL designed and performed the research; Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y and Xia Y collected the data; Zhu ht and Ai ds analyzed the data and wrote the manuscript; Tang hr, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Xia Y, Zhang Z, Guo XM, Jiang GL, and Zhao KL revised the manuscript.

**Supported by:** National Natural Science Foundation of China, No. 21172043 and No. 21441010.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Cancer Hospital affiliated with Fudan University.

**Clinical trial registration statement:** As the study started 8 years ago, at that time, we did not registered our clinical trial in website, please understand.

**Informed consent statement:** All study participants, or their legal guardian, provided written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors of this manuscript having no conflicts of interest to disclose.

**Data sharing statement:** There is no additional data available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Dr. Kuai-le Zhao**, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China. kuaile\_z@sina.com

**Telephone:** +86-21-64175590-6726

**Fax:** +86-21-64174774

**Received:** November 10, 2016

**Peer-review started:** November 13, 2016

**First decision:** December 2, 2016

**Revised:** December 16, 2016

**Accepted:** December 21, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

to evaluate the long-term effectiveness and late toxicities of paclitaxel plus cisplatin with concurrent radiotherapy for locally advanced esophageal squamous cancer.

***METHODS***

Between 2008 and 2011, 76 patients were enrolled in a phase II study on the treatment of loco-regional advanced esophageal cancer with radiotherapy (68.4 Gy/44 fractions or 61.2 Gy/34 fractions) combined with 4-cycle chemotherapy consisting of DDP (25 mg/m2 per day for 3 d) and PTX (175 mg/m2 for 3 h). The primary endpoints were overall survival rate and progression-free survival, and the secondary endpoints were toxicity and the treatment failure pattern.

***RESULTS***

A total of 76 patients were enrolled in this study, of which 63.2% finished the whole regimen. The 5-year survival rates for the per-protocol population and intent-to-treat population were 25.4% and 26.4%, respectively, and the median survival rates were 23.7 mo and 28.5 mo, respectively. Grade 3 or 4 late toxicity was observed in only one patient because of heart failure. In log-rank analysis, the pretreatment stage (II+III stage: 36.1 mo *vs* IV stage: 14.9 mo) and the completed cycle (1-3 cycles: 16.1 mo *vs* 4 cycles: 35.5 mo) were significant prognostic factors (*P* = 0.037 < 0.05 and *P* = 0.013 < 0.05).

***CONCLUSION***

Radiotherapy combined with chemotherapy consisting of PTX and DDP is a safe and effective definitive treatment for loco-regional advanced esophageal squamous cancer.

**Key words:** Loco-regional advanced esophageal cancer; Chemoradiotherapy; Long-term result; Phase II trial

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This was a prospective phase II trial with 76 patients seeking to evaluate the effect of paclitaxel plus cisplatin combined with concurrent radiotherapy for locally advanced esophageal squamous cancer. Our results showed a good survival rate, which seemed comparable or even better than other studies undergoing definitive PTX-based chemoradiotherapy.

Zhu HT, Ai DS, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL. Long-term results of TP concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. *World J Gastroenterol* 2016; In press

**introduction**

Concurrent chemoradiotherapy has been recognized as a standard treatment for loco-regional advanced unresectable esophageal cancers[1,2]. The combination of fluorouracil (5-FU) plus cisplatin (DDP) is most commonly used, with a median survival time of 16 months. However, the standard regimen remains controversial, as more radiosensitive chemotherapeutic drugs, such as paclitaxel (PTX), have been investigated in esophageal cancer[3-6]. Moreover, with the development of radiation techniques, the appropriate irradiation field and total dosage have not been clarified[7-9].

In 2008, a phase II clinical trial commenced to observe the safety and effectiveness of PTX plus DDP combined with concurrent radiotherapy for locally advanced esophageal squamous cancer. The acute toxicity and 3-year survival rates were reported in 2014[10]. Now, the aim of the present study was to update the results to show the long-term survival and late toxicity of the study for loco-regional esophageal squamous cancer. To the best of our knowledge, few long-term observations of prospective studies have been reported to date.

**MATERIALS AND METHODS**

The study was performed between July 2008 and November 2011 in Fudan University Shanghai Cancer Center. Patients were eligible for this trial if they were histologically confirmed to have loco-regional esophageal squamous cancer with no metastasis (stage II-IVa and stage IVb without viscera metastasis, UICC 6th), age ≤ 75 years, Karnofsky performance score (KPS) ≥ 80, neutrophil count of at least 1.5×109/L, leukocyte count of at least 3×109/L, platelet count of at least 100 ×109/L, serum creatinine level no greater than 1.2 mg/dL, and serum urea nitrogen level no greater than 25 mg/dL. There was no prior operation/radiotherapy/chemotherapy/target therapy without complete obstruction and tracheoesophageal fistula.

***Interventions***

We designed a phase II study of TP (PTX+DDP) concurrent radiotherapy for patients with loco-regional esophageal squamous cancer. The purpose was to evaluate the safety and effectiveness of a four-week regimen of TP (cisplatin and paclitaxel) concurrent radiotherapy (Figure 1).

At the beginning of this study, late-course accelerated radiotherapy (LCAF) was utilized because we had completed some studies of LCAF and obtained higher local control and overall survival[11,12]. The regimen of LCAF was as follows: the first phase of radiation was 41.4 Gy/ 23 fractions over 4.6 wk (1.8 Gy/fraction, 5 fractions per week). The second phase of irradiation was the accelerated hyperfractionated session of 27 Gy/18 fractions in 1.6 wk (1.5 Gy/fraction, twice daily with a minimum interval of 6 h). The total dose of LCAF was 68.4 Gy/41 fractions in 44 d. After 16 patients had completed LCAF radiotherapy, fractionated radiotherapy (twice a day) was prohibited because of the increased number of patients and the limited number of radiation machines; in particular, it was impossible for patients to receive radiation therapy twice per day. Therefore, conventional radiotherapy (CF) had to be used instead of LCAF. These patients received 61.2 Gy/34 fractions in 48 d, with 1.8 Gy/fraction 5 times per week. The regimen for TP was the same as it was previously.

For all patients, the radiotherapeutic technique was the 3-dimensional planning technique or intensity-modulated radiation therapy. The megavoltage photon energy of 6MV was used. The target volume was localized by computed tomography (CT) planning. The gross tumor volume (GTV) included the primary tumor and nodal metastasis. The clinical target volume (CTV) contained a 2 to 3-cm cephalad and caudad margin beyond the GTV. The planning target volume (PTV) was defined as having a 1-cm margin around the CTV. No prophylactic irradiation was given to any patient.

The study protocol was reviewed and approved by the Ethics Committee of the Cancer Hospital affiliated with Fudan University (No. 081065). Written informed consent was obtained from all participants.

***Follow-up and statistics***

Follow-up evaluations were performed every 3 mo during the first year, every 6 mo for the next 2 years, and then once a year thereafter. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE 3.0).

The treatment completion was defined as the fulfillment of 4 cycles of full-dose PTX+DDP along with a planed total dose of 68.4 Gy or 61.2 Gy radiotherapy.

Survival rates were calculated by the Kaplan-Meier model from the first day of treatment until death, and differences between rates were compared using the log-rank test. Age (65 years or less *vs* more than 65 years), gender (male *vs* female), stage (II-III *vs* IV: UICC 6th), number of cycles of chemotherapy (1-3 *vs* 4), pattern of radiotherapy (LCAF *vs* CF) and number of recurrent regions (one region *vs* multiple regions) were included into the log-rank test. A *P* value of less than 0.05 was considered significant. All analyses were performed using SPSS22.0.

All patients who received treatment at least once were summarized in ITT (intention to treat) analysis. The PP (per-protocol) analysis consisted of all treated patients without any protocol violation. The overall survival (OS) and progression-free survival (PFS) rates were analyzed based on ITT and PP populations, respectively. The primary endpoints of this study were OS and PFS, and the secondary endpoints were the evaluation of toxicity and the treatment failure pattern.

**Results**

Seventy-six patients (median age, 58 years; age range, 37 to 74 years) were enrolled in this phase II study from 2008 to 2011 (Table 1). Forty-eight (63.2%) patients completed the whole regimen of chemotherapy without reduction. The median follow-up time was 78.5 mo (range: 67.2-89.8 mo). In July 2016, 6 patients were lost to follow-up because they changed their phone number; 76 (100%) patients were included in the ITT population and 70 (92.1%) in the PP population. In the PP population, 17 patients were alive, and 16 had no evidence of disease progression. Among the 54 of 70 patients with treatment failure, 17 had only local recurrence, 23 had distant metastasis only, 8 had concurrent local/distant failure, and 6 had failure due to other reasons, including second primary cancer (2 patients), second primary cancer progression (3 patients), and heart failure (1 patient).

The 1-, 2-, 3-, 4-, 5-year survival rates in the PP population were 72.9%, 50%, 40%, 28.6%, and 25.4%, respectively, while those in the ITT population were 75%, 53.9%, 44.7%, 34.2%, and 26.4%, respectively. The median OS and PFS times were 23.7 mo (95%CI: 13.0-34.4) and 13.3 mo (95%CI: 9.7-16.9) in the PP population and 28.5 mo (95%CI: 15.2-41.8), and 14.7 mo (95%CI: 10.7-18.7) in the ITT population, respectively (Figure 2).

In log-rank analysis, the difference between the OS rate in the pretreatment stage (*P =* 0.037; II+III stage: 36.1 mo, 95%CI: 22.9-49.2 *vs* IV stage: 14.9 mo, 95%CI: 11.9-17.9) and the completed cycle (*P =* 0.013; 1-3 cycles: 16.1 mo, 95%CI: 10.2-22.1 *vs* 4 cycles: 35.5 mo, 95%CI: 22.3-48.7) was statistically significant (Table 2).

As acute toxicities had been reported previously[10], the late toxicities were updated in this article. Only one patient died because of heart failure at 20 mo, although it was not clear whether this was caused by radiotherapy. Other grade 3 or 4 late toxicities were not detected, although grade 1 or 2 focal pulmonary fibrous changes and pericardial effusion were common. Moreover, among the alive patients, only 2 patients had grade 1 Hematological toxicity, which did not need special treatment.

**Discussion**

Localized esophageal carcinoma is often treated with preoperative chemoradiotherapy; however, when carcinoma is unresectable (IV stage) or patients do not want to undergo surgery, concurrent chemoradiotherapy would be a suitable treatment[13-15]. Some trials have revealed the effectiveness of chemoradiotherapy on loco-regional advanced esophageal cancer[1,2,16,17], and 5-FU plus DDP with concurrent radiotherapy was recognized as the initial strategy. As a promising agent, PTX was reported to be effective on concurrent chemoradiotherapy due to its good response rate of 40%[18,19] and its effect as a radio-sensitizer. Various scientists have reported the efficacy of PTX-based chemoradiotherapy, especially TP (PTX plus DDP) and TF (PTX plus 5-FU). However, the details of the regimen remain controversial, including the dosage and the number of cycles.

In this study, we investigated the effectiveness of a 4-wk schedule of PTX plus DDP combined with concurrent radiotherapy. Our results showed good survival rates, with 1-, 2-, 3-, 4-, and 5-year survival rates of 75%, 53.9%, 44.7%, 34.2%, and 26.4%, respectively, in the ITT model. These results seemed comparable or even better than those with RTOG 0113 and other studies of patients undergoing definitive PTX-based chemoradiotherapy (Table 3).

Compared with the study of Song *et al*[20], who used a similar regimen as in our study, the 2-year survival rate in our study was much higher (53.9% *vs* 40.8%), while the acute and late toxicity were comparable even with a higher dose of PTX. These differences may be due to the following reasons: (1) the median age in our study was 54, while the previous authors enrolled much older patients; and (2) the radiation delivery schedule was different. However, a few trials have reported the long-term outcome of regimens involving PTX in unresectable esophageal cancer[20,21]. In our study, the 5-year survival rate (26.4% in ITT model) was comparable to that of RTOG 8501 (26%), which used the combination of DDP+5-FU[2]. This finding supports the idea that 4-wk-based PTX plus DDP concurrent radiotherapy is effective in treating local advanced esophageal cancer, easy to perform and saves time spent in transportation to the treatment center.

The standard radiation regimen is 50.4 Gy/28 fractions in Western countries, and whether a high dosage of radiation can be used in concurrent therapy remains controversial. In the INT 0123 study reported by Minsky *et al*[1] the higher radiation dose (64.8 Gy) did not increase the OS or local control compared with the standard irradiation dose (50.4 Gy), although the higher dosage did not cause greater late toxicity. However, in Asia, 60-70 Gy radiation doses are widely used. In Jingu’s study, the median OS was 39 months, which was excellent after 60 Gy irradiation[22]. In our study, only 1 patient died of heart failure, and whether this outcome had any relationship with late toxicity was unclear. The most common late toxicity was grade 1 or 2 focal pulmonary fibrous changes. Considered a good OS, this result suggests that a radiation dose of more than 60 Gy is appropriate for loco-regional advanced esophageal cancer[22,23]. Differences in radiation doses between Asian and Western countries might be because of the distinct radiation plan applied.

In our hospital, LCAF was investigated for more than 10 years and was confirmed to be safe and show a better local control or 5-year OS rate[11,12]. However, phase III trials are still needed to compare this approach with CF. The primary purpose of this study was to assess the effectiveness of TP with concurrent LCAF, but because of the limited number of radiation machines and the large number of patients, it was impossible for one patient to receive radiotherapy twice daily; thus, CF was used instead of LCAF in the other 60 patients. From the final data, there were no significant differences between LCAF and CF, perhaps because of the limited number of patients. Considered to offer economic benefit, CF is recommended for loco-regional advanced esophageal cancer.

The combination of 4-wk TP chemotherapy with concurrent radiation (61.2 Gy/34 fractions) is a safe and promising definitive treatment for loco-regional advanced esophageal squamous cancer. A phase III randomized clinical trial (NCT 02459457) has since been initiated to compare the efficacy among TP, TF (PTX plus 5-FU) and TC (PTX plus carboplatin) to determine the best PTX-based regimen for concurrent chemoradiotherapy.

**COMMENTS**

***Background***

Concurrent chemoradiotherapy has been recognized as a standard treatment for loco-regional advanced unresectable esophageal cancers. The combination of fluorouracil (5-FU) plus cisplatin (DDP) was mostly used. Paclitaxel (PTX) was investigated to against esophageal cancer. The current trial was designed to evaluate the safety and effectiveness of PTX plus DDP combined with concurrent radiotherapy for locally advanced esophageal squamous cancer.

***Research frontiers***

Various scientists have reported the efficacy of PTX-based chemoradiotherapy, especially TP (PTX plus DDP) and TF (PTX plus 5-FU) for locally advanced esophageal squamous cancer, but the details of the regimen remain controversial, including the dosage and the number of cycles. In this study, a 4-cycle TP regimen concurrent radiotherapy showed a good overall survival rate and low toxicity.

***Innovations and breakthroughs***

Few long-term observations of prospective studies about treating effectiveness of locally advanced esophageal squamous cancer have been reported to date.

***Applications***

Based on this result, a phase III randomized clinical trial (NCT 02459457) has since been initiated to compare the efficacy among TP, TF (PTX plus 5-FU) and TC (PTX plus carboplatin) to determine the best PTX-based regimen for concurrent chemoradiotherapy.

***Terminology***

Paclitaxel was isolated from the bark of the Pacific yew, Taxus brevifolia, used to treat ovarian, breast, lung, pancreatic and other cancers. Cisplatin reacted in the body, binded to DNA and caused the DNA strands to crosslink, which ultimately triggered cells to die in a programmed way.

***Peer-review***

The authors report the long-term results of a combined chemoradiation regimen for esophageal cancer, which is interesting.

**References**

1 **Minsky BD**, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002; **20**: 1167-1174 [PMID: 11870157 DOI: 10.1200/JCO.2002.20.5.1167]

2 **Cooper JS**, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999; **281**: 1623-1627 [PMID: 10235156 DOI: 10.1001/jama.281.17.1623]

3 **Ilson DH**, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. *J Clin Oncol* 1998; **16**: 1826-1834 [PMID: 9586897 DOI: 10.1200/jco.1998.16.5.1826]

4 **Adelstein DJ**, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. *J Clin Oncol* 2000; **18**: 2032-2039 [PMID: 10811667 DOI: 10.1200/jco.2000.18.10.2032]

5 **Hsu FM**, Lin CC, Lee JM, Chang YL, Hsu CH, Tsai YC, Lee YC, Cheng JC. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. *J Surg Oncol* 2008; **98**: 34-41 [PMID: 18449912 DOI: 10.1002/jso.21063]

6 **Polee MB**, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. *Br J Cancer* 2002; **86**: 669-673 [PMID: 11875723 DOI: 10.1038/sj.bjc.6600166]

7 **Jingu K**, Ariga H, Nemoto K, Narazaki K, Umezawa R, Takeda K, Koto M, Sugawara T, Kubozono M, Miyata G, Onodera K, Yamada S. Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer. *Int J Radiat Oncol Biol Phys* 2012; **83**: 172-177 [PMID: 22079727 DOI: 10.1016/j.ijrobp.2011.06.1978]

8 **Tahara M**, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, Kato K, Yamazaki K, Muro K, Takaishi H, Boku N, Ohtsu A. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). *Cancer Sci* 2015; **106**: 1414-1420 [PMID: 26250827 DOI: 10.1111/cas.12764]

9 **Yamoah K**, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. *Int J Radiat Oncol Biol Phys* 2015; **93**: 737-745 [PMID: 26530740 DOI: 10.1016/j.ijrobp.2015.07.2284]

10 **Tang HR**, Ma HF, An SM, Badakhshi H, Deng JY, Zhang JH, Chen Y, Zhang Z, Guo XM, Jiang GL, Zhao KL. A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma. *Am J Clin Oncol* 2016; **39**: 350-354 [PMID: 24732811 DOI: 10.1097/COC.0000000000000069]

11 **Shi XH**, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. *Radiother Oncol* 1999; **51**: 21-26 [PMID: 10386713 DOI: 10.1016/S0167-8140(99)00017-1]

12 **Zhao KL**, Shi XH, Jiang GL, Wang Y. Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2004; **60**: 123-129 [PMID: 15337547 DOI: 10.1016/j.ijrobp.2004.02.058]

13 **Sjoquist KM**, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol* 2011; **12**: 681-692 [PMID: 21684205 DOI: 10.1016/s1470-2045(11)70142-5]

14 **Fan M**, Lin Y, Pan J, Yan W, Dai L, Shen L, Chen K. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis. *Thorac Cancer* 2016; **7**: 173-181 [PMID: 27042219 DOI: 10.1111/1759-7714.12299]

15 **Jin HL**, Zhu H, Ling TS, Zhang HJ, Shi RH. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. *World J Gastroenterol* 2009; **15**: 5983-5991 [PMID: 20014464 DOI: 10.3748/wjg.15.5983]

16 **Ajani JA**, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. *J Clin Oncol* 2008; **26**: 4551-4556 [PMID: 18574157 DOI: 10.1200/JCO.2008.16.6918]

17 **al-Sarraf M**, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. *J Clin Oncol* 1997; **15**: 277-284 [PMID: 8996153 DOI: 10.1200/jco.1997.15.1.277]

18 **Shirakawa T**, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. *Cancer Chemother Pharmacol* 2014; **74**: 1207-1215 [PMID: 25267597 DOI: 10.1007/s00280-014-2597-3]

19 **Kato K**, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. *Cancer Chemother Pharmacol* 2011; **67**: 1265-1272 [PMID: 20703479 DOI: 10.1007/s00280-010-1422-x]

20 **Song T**, Zhang X, Fang M, Wu S. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer. *Onco Targets Ther* 2015; **8**: 3087-3094 [PMID: 26543377 DOI: 10.2147/OTT.S92537]

21 **Tu L**, Sun L, Xu Y, Wang Y, Zhou L, Liu Y, Zhu J, Peng F, Wei Y, Gong Y. Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma. *Radiat Oncol* 2013; **8**: 75 [PMID: 23531325 DOI: 10.1186/1748-717x-8-75]

22 **Jingu K**, Nemoto K, Matsushita H, Takahashi C, Ogawa Y, Sugawara T, Nakata E, Takai Y, Yamada S. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. *BMC Cancer* 2006; **6**: 50 [PMID: 16515704 DOI: 10.1186/1471-2407-6-50]

23 **Zhang J**, Peng F, Li N, Liu Y, Xu Y, Zhou L, Wang J, Zhu J, Huang M, Gong Y. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. *Radiat Oncol* 2012; **7**: 93 [PMID: 22713587 DOI: 10.1186/1748-717X-7-93]

**P-Reviewer:** Bonavina L, Sterpetti AV **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Schedule of the chemoradiotherapy protocol.** LCAF radiotherapy consisted of 41.4 Gy (1.8 Gy/fraction, q.d.) using large fields, 27 Gy (1.5 Gy/fraction, b.i.d.) using reduced fields, with a total dose of 68.4 Gy/41 fractions in 44 d. CF radiotherapy consisted of 61.2 Gy/34 fractions in 48 d (1.8 Gy/fraction, q.d.). The chemotherapy regimen included PTX at 175 mg/m2, D1 and DDP at 25 mg/m2, D1-3. RT: radiotherapy; LCAF: late-course accelerated radiotherapy; CF: conventional radiotherapy; DDP*:* Cisplatin; PTX: Paclitaxel.

**Table 1 Patients’ characteristics**

|  |  |
| --- | --- |
| **Characteristic** | ***n*(%)** |
| Age(yr) |  |
| Median | 58(37-74) |
| Gender |  |
| Male | 63(82.9) |
| Female | 13(17.1) |
| Stage1 |  |
| II | 21(27.6) |
| III | 27(35.5) |
| IV | 28(30.3) |
| Fraction refimen |  |
| LCAF | 16(21.1) |
| CF | 60(78.9) |
| Number of chemotherapy cycle |  |
| 1 | 8(10.5) |
| 2 | 13(17.1) |
| 3 | 7(9.2) |
| 4 | 48(63.2) |
| Statement |  |
| Survive | 17(22.4) |
| Dead | 53(69.7) |
| Lost of follow up | 6(7.9) |

1UICC 6th. LCAF: Late-course accelerated radiotherapy; CF: Conventional radiotherapy; UICC: Union for international cancer control.



**Figure 2 Overall survival and progression-free survival rates in patients with loco-regional advanced esophageal cancer (Kaplan-Meier method).** A: ITT analysis; B: PP analysis. ITT: Intention to treat; PP: Per-protocol.

**Table 2 Prognostic factors for overall survival**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factor** |  | **No.** | **Median survival time(mo)** | **Log-rank** |
| Cycle | 1-3 | 26 | 16.1 | 0.013 |
| 4 | 50 | 35.5 |
| Stage | II-III | 48 | 36.1 | 0.037 |
| IV | 28 | 14.9 |
| Gender | Male | 63 | 17.3 | 0.093 |
| Female | 13 | 35.5 |
| Age | < 65 yr | 58 | 23.4 | 0.708 |
| ≥ 65 yr | 18 | 27.0 |
| Radiation | CF | 60 | 23.4 | 0.626 |
| LCAF | 16 | 28.5 |

CF: Conventional radiotherapy; LCAF: Late-course accelerated radiotherapy.

**Table 3 Results of TP regimen plus radiotherapy for loco-regional advanced esophageal cancer in past studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **No.** | **Chemotherapy** | **Dose and fraction** | **Grade≥3 acute hematologic toxicity** | **Median observation period(mo)** | **Median survival time(mo)** | **2-yr survival rate** |
| Jingu *et al*[22] | 84 | PTX 135 mg/m2 | 50.4 Gy/28 fractions | 40.00% | NA | 14.9 | 37.00% |
|  | DDP 75 mg/m2 | |  |  |  |  |
|  | 3-wk based | |  |  |  |  |
| Tu *et al*[21] | 36 | PTX 135 mg/m2 | 52-70 Gy/1.8-2 fractions | 13.90% | 14 | 18 | 42.80% |
|  | DDP 75 mg/m2 | |  |  |  |  |
|  | 3-wk based | |  |  |  |  |
| Song *et al*[20] | 82 | PTX 135 mg/m2 | 60 Gy/30 fractions | 30.50% | 20.4 | 18.2 | 40.80% |
|  | DDP 30 mg/m2 | |  |  |  |  |
|  | 4-wk based | |  |  |  |  |

DDP*:* Cisplatin; PTX: Paclitaxel; RT: Radiotherapy; NA: Not available.